诺泰生物(688076) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥140,873,674.91, representing a decrease of 11.09% compared to the same period last year[6]. - The net profit attributable to shareholders for Q3 2021 was ¥21,864,514.31, down 38.42% year-over-year[6]. - The net profit after deducting non-recurring gains and losses for Q3 2021 was ¥18,359,658.26, a decrease of 30.80% compared to the previous year[9]. - Net profit for the third quarter of 2021 was ¥69,525,337.97, compared to ¥78,888,059.93 in the third quarter of 2020, indicating a decrease of about 11.5%[37]. - Basic earnings per share for Q3 2021 were ¥0.10, down 54.55% year-over-year[9]. - The basic earnings per share for the third quarter of 2021 was ¥0.40, down from ¥0.52 in the same quarter of 2020, reflecting a decrease of approximately 23.1%[40]. - The company's return on assets (ROA) for Q3 2021 was 1.25%, a decrease of 2.68 percentage points compared to the previous year[9]. Assets and Equity - The total assets at the end of the reporting period were ¥2,026,842,599.47, an increase of 45.23% compared to the end of the previous year[9]. - The equity attributable to shareholders at the end of the reporting period was ¥1,767,847,999.98, up 83.51% year-over-year[9]. - The total current assets have increased to ¥1,028,831,337.92 from ¥487,908,101.27 year-over-year[30]. - The total assets of the company as of September 30, 2021, are ¥2,026,842,599.47, compared to ¥1,395,573,459.13 at the end of 2020[30]. - The total non-current assets have increased to ¥998,011,261.55 from ¥907,665,357.86 year-over-year[30]. - The total equity attributable to shareholders reached ¥1,767,847,999.98, significantly increasing from ¥963,343,985.32 in the previous year, marking a growth of approximately 83.6%[35]. Cash Flow - The cash flow from operating activities for the year-to-date was ¥131,827,280.03, an increase of 32.04% compared to the previous year[9]. - Operating cash inflow for the first three quarters of 2021 was RMB 554,516,533.82, an increase of 32.5% compared to RMB 418,439,683.58 in the same period of 2020[45]. - Net cash flow from operating activities for the first three quarters of 2021 was RMB 131,827,280.03, up from RMB 99,840,845.29 in 2020, representing a growth of 32.1%[45]. - The ending balance of cash and cash equivalents as of the end of the reporting period was RMB 518,246,380.64, compared to RMB 72,935,999.09 at the end of the previous year[47]. - The company reported a cash inflow of RMB 762,629,380.06 from new investments in 2021, reflecting strong investor confidence[47]. Expenses - Research and development expenses for Q3 2021 totaled ¥13,769,947.43, a decrease of 38.41% compared to the same period last year[9]. - Research and development expenses for the first three quarters of 2021 amounted to ¥44,422,127.37, slightly up from ¥43,349,679.30 in the same period of 2020, reflecting a growth of approximately 2.5%[36]. - The company's total operating costs for the first three quarters of 2021 were ¥362,873,515.63, compared to ¥304,705,301.11 in the same period of 2020, which is an increase of about 19.1%[36]. - The company experienced an increase in management and sales expenses, contributing to the decline in net profit[16]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 12,846[19]. - The largest shareholder, Lianyungang Nuotai Investment Management Partnership, holds 20,000,000 shares, accounting for 9.38% of the total shares[19]. - The second and third largest shareholders, Zhao Deyi and Zhao Dezhong, each hold 13,414,000 shares, representing 6.29% of the total shares[19]. - The company has no pledged, marked, or frozen shares among the top shareholders[19]. - The company has not disclosed any significant related party transactions or agreements among shareholders beyond the known relationships[26]. Liabilities - The total liabilities of the company as of the latest report were ¥259,019,473.73, down from ¥429,548,577.85 in the previous period, showing a reduction of about 39.8%[33]. - The total non-current liabilities were reported at ¥44,809,096.01, a slight decrease from ¥47,338,215.16 in the previous period, showing a reduction of approximately 5.3%[33].